title: SGLT2-inhibitors in type-2 diabetes: The remaining questions!
abstract: As the SGLT2-i therapy progressively carves out a forte in the management of diabetes, multiple equally significant questions justly occupy the medical mind. Aspects pertinent to the influence of this therapy on the renal pathophysiology, the prevention of cardiovascular disease, and considerations for their safe use, hold immense relevance to clinical practice. This review attempts to make an appropriate clinical interpretation of the existing evidence, to evolve a practical perspective on some of these yet unanswered aspects.
authors.affiliation: Department of Endocrinology, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences (PGIMS)-Rohtak, Rohtak, Haryana 124001, India. Electronic address: rajputrajmeena@hotmail.com.
authors.forename: Rajesh
authors.initials: R
authors.lastname: Rajput
authors.affiliation: Boehringer Ingelheim (India) Pvt. Ltd., 10th Floor, Hallmark Plaza, Bandra East, Mumbai, Maharashtra 400051, India. Electronic address: jignesh.ved@boehringer-ingelheim.com.
authors.forename: Jignesh
authors.initials: J
authors.lastname: Ved
mesh_terms: D001559:Benzhydryl Compounds / Q000009:adverse effects / Q000627:therapeutic use; D000068896:Canagliflozin / Q000009:adverse effects / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005960:Glucosides / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007668:Kidney / Q000187:drug effects; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors
chemical_list: D001559:Benzhydryl Compounds; D005960:Glucosides; D007004:Hypoglycemic Agents; C089180:SLC5A2 protein, human; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D000068896:Canagliflozin; C529054:dapagliflozin
keywords: Causation creep; Glucuretic kidney; Karma of glucuresis